Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age.
Saved in:
| Title: | Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. |
|---|---|
| Authors: | Kulkarni, J, Gavrilidis, E, Wang, W, Worsley, R, Fitzgerald, P B, Gurvich, C, Van Rheenen, T, Berk, M, Burger, H |
| Source: | Molecular Psychiatry. Jun2015, Vol. 20 Issue 6, p695-702. 8p. |
| Subjects: | Estradiol, Schizophrenia treatment, Randomized controlled trials, People with schizophrenia, Schizoaffective disorders, Psychoses, Antipsychotic agents |
| Abstract: | Many women with schizophrenia remain symptomatic despite optimal use of current therapies. While previous studies suggest that adjunctive oestrogen therapy might be effective, large-scale clinical trials are required before clinical applications are possible. This study is the first large-scale randomized-controlled trial in women with treatment-resistant schizophrenia. This Definitive Oestrogen Patch Trial was an 8-week, three-arm, double-blind, randomized-controlled trial conducted between 2006 and 2011. The 183 female participants were aged between 18 and 45 (mean=35 years), with schizophrenia or schizoaffective disorder and ongoing symptoms of psychosis (Positive and Negative Syndrome Scale, PANSS score>60) despite a stable dose of antipsychotic medication for at least 4 weeks. Mean duration of illness was more than 10 years. Participants received transdermal estradiol 200 μg, transdermal estradiol 100 μg or an identical placebo patch. For the 180 women who completed the study, the a priori outcome measure was the change in PANSS score measured at baseline and days 7, 14, 28 and 56. Cognition was assessed at baseline and day 56 using the Repeatable Battery of Neuropsychological Status. Data were analysed using latent growth curve modelling. Both estradiol groups had greater decreases in PANSS positive, general and total symptoms compared with the placebo group (P<0.01), with a greater effect seen for 200 μg than 100 μg estradiol. The largest effect size was for the positive subscale of PANSS in the estradiol 200 μg treatment group (effect size 0.44, P<0.01). This study shows estradiol is an effective and clinically significant adjunctive therapy for women with treatment-resistant schizophrenia, particularly for positive symptoms. [ABSTRACT FROM AUTHOR] |
| Copyright of Molecular Psychiatry is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 102779117 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Kulkarni%2C+J%22">Kulkarni, J</searchLink><br /><searchLink fieldCode="AR" term="%22Gavrilidis%2C+E%22">Gavrilidis, E</searchLink><br /><searchLink fieldCode="AR" term="%22Wang%2C+W%22">Wang, W</searchLink><br /><searchLink fieldCode="AR" term="%22Worsley%2C+R%22">Worsley, R</searchLink><br /><searchLink fieldCode="AR" term="%22Fitzgerald%2C+P+B%22">Fitzgerald, P B</searchLink><br /><searchLink fieldCode="AR" term="%22Gurvich%2C+C%22">Gurvich, C</searchLink><br /><searchLink fieldCode="AR" term="%22Van+Rheenen%2C+T%22">Van Rheenen, T</searchLink><br /><searchLink fieldCode="AR" term="%22Berk%2C+M%22">Berk, M</searchLink><br /><searchLink fieldCode="AR" term="%22Burger%2C+H%22">Burger, H</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Molecular+Psychiatry%22">Molecular Psychiatry</searchLink>. Jun2015, Vol. 20 Issue 6, p695-702. 8p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Estradiol%22">Estradiol</searchLink><br /><searchLink fieldCode="DE" term="%22Schizophrenia+treatment%22">Schizophrenia treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Randomized+controlled+trials%22">Randomized controlled trials</searchLink><br /><searchLink fieldCode="DE" term="%22People+with+schizophrenia%22">People with schizophrenia</searchLink><br /><searchLink fieldCode="DE" term="%22Schizoaffective+disorders%22">Schizoaffective disorders</searchLink><br /><searchLink fieldCode="DE" term="%22Psychoses%22">Psychoses</searchLink><br /><searchLink fieldCode="DE" term="%22Antipsychotic+agents%22">Antipsychotic agents</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Many women with schizophrenia remain symptomatic despite optimal use of current therapies. While previous studies suggest that adjunctive oestrogen therapy might be effective, large-scale clinical trials are required before clinical applications are possible. This study is the first large-scale randomized-controlled trial in women with treatment-resistant schizophrenia. This Definitive Oestrogen Patch Trial was an 8-week, three-arm, double-blind, randomized-controlled trial conducted between 2006 and 2011. The 183 female participants were aged between 18 and 45 (mean=35 years), with schizophrenia or schizoaffective disorder and ongoing symptoms of psychosis (Positive and Negative Syndrome Scale, PANSS score>60) despite a stable dose of antipsychotic medication for at least 4 weeks. Mean duration of illness was more than 10 years. Participants received transdermal estradiol 200 μg, transdermal estradiol 100 μg or an identical placebo patch. For the 180 women who completed the study, the a priori outcome measure was the change in PANSS score measured at baseline and days 7, 14, 28 and 56. Cognition was assessed at baseline and day 56 using the Repeatable Battery of Neuropsychological Status. Data were analysed using latent growth curve modelling. Both estradiol groups had greater decreases in PANSS positive, general and total symptoms compared with the placebo group (P<0.01), with a greater effect seen for 200 μg than 100 μg estradiol. The largest effect size was for the positive subscale of PANSS in the estradiol 200 μg treatment group (effect size 0.44, P<0.01). This study shows estradiol is an effective and clinically significant adjunctive therapy for women with treatment-resistant schizophrenia, particularly for positive symptoms. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Molecular Psychiatry is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=102779117 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/mp.2014.33 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 8 StartPage: 695 Subjects: – SubjectFull: Estradiol Type: general – SubjectFull: Schizophrenia treatment Type: general – SubjectFull: Randomized controlled trials Type: general – SubjectFull: People with schizophrenia Type: general – SubjectFull: Schizoaffective disorders Type: general – SubjectFull: Psychoses Type: general – SubjectFull: Antipsychotic agents Type: general Titles: – TitleFull: Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Kulkarni, J – PersonEntity: Name: NameFull: Gavrilidis, E – PersonEntity: Name: NameFull: Wang, W – PersonEntity: Name: NameFull: Worsley, R – PersonEntity: Name: NameFull: Fitzgerald, P B – PersonEntity: Name: NameFull: Gurvich, C – PersonEntity: Name: NameFull: Van Rheenen, T – PersonEntity: Name: NameFull: Berk, M – PersonEntity: Name: NameFull: Burger, H IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: Jun2015 Type: published Y: 2015 Identifiers: – Type: issn-print Value: 13594184 Numbering: – Type: volume Value: 20 – Type: issue Value: 6 Titles: – TitleFull: Molecular Psychiatry Type: main |
| ResultId | 1 |
